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Background: We aimed to describe patterns of use and characteristics of 10 commonly used antidepressants for
the period 2009–2014 in Denmark, Germany, Spain, and Sweden.
Methods: Adult initiators from 2009 to 2014 of each study antidepressant were identified in four countries using
five data sources: the Danish National registers, GePaRD (Germany), EpiChron (Aragon, Spain), SIDIAP
(Catalonia, Spain), and the Swedish National Registers. The study included 10 study antidepressants: citalopram,
escitalopram, fluoxetine, paroxetine, sertraline, duloxetine, venlafaxine, amitriptyline, mirtazapine, and ago-
melatine.
Results: Citalopram was the most prescribed study antidepressant, followed by mirtazapine. Paroxetine and
agomelatine were the least prescribed antidepressants. Mirtazapine was widely used among older antidepressant
initiators with higher percentages of comorbidities at baseline, and fluoxetine was used among young patients.
Citalopram and amitriptyline had the lowest percentage of multiple antidepressant use in the 12 months prior to
the current treatment episode, while agomelatine, duloxetine, and venlafaxine had the highest percentage of
multiple antidepressant use in the year prior to the current treatment episode.
Limitations: The most important limitations are exposure information based on filled prescriptions, focus on
antidepressant initiators only, lack of information on the indication, and heterogeneity of the type of data across
data sources.
Conclusions: Results of this study including 4.8 million study antidepressant initiators of study antidepressants
suggest that citalopram and mirtazapine are the most commonly prescribed antidepressants. Agomelatine and
paroxetine were the least used antidepressants in the participating populations. Mirtazapine was the anti-
depressant most commonly prescribed among older antidepressant initiators with high percentage of co-
morbidities at baseline, whereas fluoxetine was commonly used among young patients.
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1. Introduction
Antidepressants are among the most prescribed drugs in Europe.
Besides depression as the major indication, antidepressants are also
used for a wide range of other conditions such as panic disorders,
generalized anxiety disorder, and neuropathic pain (Noordam et al.,
2015). The most recent drug utilization studies conducted in Europe
suggest an increase in the use of antidepressants over time, particularly
for selective serotonin reuptake inhibitors (SSRIs), the most commonly
prescribed type of antidepressant class (Abbing-Karahagopian et al.,
2014; Bauer et al., 2008; Noordam et al., 2015; Poluzzi et al., 2013).
In past decades, the number of antidepressants available on the
market has increased markedly, resulting in a great variety of treatment
options for prescribers. The choice of an antidepressant is influenced by
several factors, including those specifically related to the drug profile
(e.g. side effects, tolerability, and cost), physician characteristics (e.g.
specialty, country of practice), reimbursement policies (Bauer et al.,
2008), and patient characteristics, such as severity of depression and
presence of comorbidities (Jobski et al., 2017b; Zimmerman et al.,
2004).
With the exception of one German study restricted to adults older
than 65 years (Jobski et al., 2017b), no studies have analysed the use of
antidepressants in adults from the general population in several Eur-
opean countries since 2012. Also, little information is available on the
patterns of comorbidities among initiators of different antidepressant
drugs. Therefore, we aimed to describe the cumulative incidence of
initiators of 10 commonly prescribed antidepressants for the period
2009–2014 in Denmark, Germany, Spain, and Sweden. We also aimed
to compare the characteristics of initiators of each of the 10 study an-
tidepressants in terms of their demographic characteristics, presence of
comorbidities, health care resource use, and patterns of use.
2. Methods
2.1. Study setting
This drug utilization study was conducted using data collected
during a postauthorisation safety study investigating the potential risk
of acute hepatoxic reactions associated with the use of agomelatine and
other antidepressants (Pladevall, 2018). Initiators of each study anti-
depressant were identified in four countries using five automated health
data sources: the Danish National Health Registers (Denmark)
(Pottegard et al., 2016; Schmidt et al., 2015), the German Pharma-
coepidemiological Research Database (GePaRD) (Germany) (Jobski
et al., 2017a,b; Pigeot and Ahrens, 2008), the EpiChron Cohort from
Aragon Health Sciences Institute (Aragon, Spain) (Prados-Torres et al.,
2018), the Information System for Research in Primary Care (SIDIAP)
(Catalonia, Spain) (SIDIAP, 2014), and the Swedish National Registers
(Sweden) (Ludvigsson et al., 2011; Wettermark et al., 2007). The main
characteristics of each database are described in Supplementary
Table 1. The study period in each data source started after the launch of
agomelatine in each respective country (2009 or 2010) and ended on
the last year for which data was available in each data source (2013 or
2014).
2.2. Study population
The study cohort included all adult initiators of any of the 10 re-
levant antidepressants in the study databases from 2009 to 2014 with at
least 12 months of continuous enrolment in the data source. The study
cohort included all individuals aged 18 years or older at the date of the
first-recorded prescription fill for any of the study antidepressants
during the study period(s) with no prescription fill for the same study
antidepressant within the prior 12 months (initiators). One patient
could contribute to several antidepressant groups if eligibility criteria
were accomplished. For women, pregnancy at the start date of
antidepressant use was an exclusion criterion.
2.3. Study antidepressants
The selected study antidepressants included five SSRIs (citalopram,
escitalopram, fluoxetine, paroxetine, and sertraline), two serotonin-
norepinephrine reuptake inhibitors (SNRIs) (duloxetine and venla-
faxine), one tricyclic antidepressant (TCA) (amitriptyline), one nora-
drenaline and specific serotonergic antidepressants (NASSAs) (mirta-
zapine), and one melatonergic agonist and 5-HT2C antagonist
(agomelatine) (Supplementary Table 2). These antidepressants were
selected in the agomelatine postauthorisation safety study to represent
(1) the most commonly used antidepressants in the participating
countries and (2) different classes of antidepressants. Agomelatine was
selected for regulatory reasons as the main exposure of interest
(Pladevall, 2018). Specific details on the exposure definition are in-
cluded in Supplementary Methods. Indication of use of study anti-
depressants for the study population was not available.
2.4. Characterisation of initiators of study antidepressants
Initiators of the study antidepressants were characterised at the date
of their first prescription according to age and sex. Comorbidity in-
formation at any time before cohort inclusion was ascertained through
hospital discharge diagnoses and diagnoses reported in primary care,
when available, in combination with information on the use of medi-
cations for specific diseases when applicable (Pladevall, 2018). In-
formation on hospitalisations during the 12 months prior to the current
treatment episode was also collected as a measure of health care utili-
sation.
Patterns of antidepressant use were also assessed. First, we mea-
sured the recent use of any antidepressant (N06A group) available on
the market at the time of the study (0, 1, 2, or more) in the 12 months
prior to the current treatment episode. Switching and multiple uses
were not differentiated but rather combined into a single variable. We
also measured the duration of the first treatment episode of current use
(in months). Finally, we measured whether the study antidepressants
were prescribed alone or combined with other antidepressants by cal-
culating the percentage of treatment episodes of current use with
combined use of another antidepressant.
2.5. Statistical analyses
Data describing the study population and prescribing patterns of
antidepressants are presented as means, standard deviations, fre-
quencies, or percentages, as appropriate. The estimated cumulative
incidence of antidepressant initiation at the end of the study period was
calculated overall and for each antidepressant by dividing the total
number of initiators and the number of initiators for each study anti-
depressant during the study period (2009–2013/2014) by the total re-
ference adult population in each data source at the end of 2013 or 2014
(depending on the end of the study period). Stata (version 14) or SAS
(version 9.4 or later) was used for the analyses by the different study
research partners evaluating each of the individual data sources.
3. Results
The study included a total of 4,833,774 initiators of antidepressants
(Table 1). Sweden had the largest population with 1.8 million initiators
of study antidepressants, followed by GePaRD (Germany) with 1.7
million, Denmark with 0.8 million, and the Spanish populations (Epi-
Chron [Aragon] and SIDIAP [Catalonia]) with less than 0.3 million
each.
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3.1. Demographic characteristics of antidepressant initiators
Women comprised the majority of initiators for all antidepressants
(Table 1). The study antidepressant with the highest proportion of
women initiators was fluoxetine (>70% in four of five populations). In
general, fluoxetine was prescribed to younger patients (median age
range, 38 years in Sweden to 50 years in Aragon [Spain]), and mirta-
zapine was consistently prescribed to older patients (median range, 54
years in Denmark to 67 years in Aragon [Spain]). Among SSRIs, cita-
lopram was commonly prescribed among older patients (range, 51
years in Denmark to 63 years in Aragon [Spain]).
3.2. Incidence of antidepressant initiation
The highest total cumulative incidence of antidepressant initiation
for the 10 antidepressants (as per 1000 population) during the period
2009 and 2013/2014 (depending on data source) was found in Sweden
with 234, followed by Denmark, 213; Aragon (Spain), 192; Catalonia
(Spain), 187; and Germany, 162 (Table 2). Overall, citalopram was the
most prescribed study antidepressant, except in Aragon (Spain), with a
cumulative incidence ranging from 10 per 1000 population in Aragon
(Spain) to 65 per 1000 population in Denmark. In Aragon (Spain), the
most prescribed study antidepressant was escitalopram, with a cumu-
lative incidence of 48 per 1000 population. For the other SSRIs, we
observed higher rates for sertraline in Denmark and Sweden when
compared with other populations. In contrast, rates for fluoxetine and
paroxetine were higher in Aragon and Catalonia populations than in the
other populations. The use of duloxetine and venlafaxine was similar in
all populations, with a higher cumulative incidence for venlafaxine
when compared with that for duloxetine, except in Aragon (Spain).
Table 1
Number of study antidepressant initiators with age and sex distribution.
Denmark GePaRD, Germany EpiChron, Aragon, Spain SIDIAP, Catalonia, Spain Sweden
Study period
Number of study antidepressant initiators, n (%)
Citalopram 253,531 (30%) 463,794 (27%) 10,412 (5%) 53,076 (20%) 405,944 (22%)
Escitalopram 57,184 (7%) 77,765 (5%) 52,256 (25%) 29,429 (11%) 141,701 (8%)
Fluoxetine 18,448 (2%) 66,782 (4%) 17,045 (8%) 23,784 (9%) 77,044 (4%)
Paroxetine 18,968 (2%) 50,141 (3%) 26,213 (12%) 38,883 (15%) 34,666 (2%)
Sertraline 137,644 (16%) 88,200 (5%) 12,899 (6%) 28,101 (11%) 359,636 (20%)
Duloxetine 37,514 (4%) 79,456 (5%) 23,744 (11%) 13,509 (5%) 86,454 (5%)
Venlafaxine 87,390 (10%) 147,580 (9%) 11,951 (6%) 15,577 (6%) 130,716 (7%)
Amitriptyline 39,404 (5%) 309,377 (18%) 22,716 (11%) 33,870 (13%) 204,078 (11%)
Mirtazapine 167,020 (20%) 370,741 (22%) 23,971 (11%) 20,324 (8%) 347,596 (19%)
Agomelatine 21,941 (3%) 62,009 (4%) 10,077 (5%) 4167 (2%) 19,046 (1%)
Total 839,044 1,715,845 211,284 260,720 1,806,881
Women (%)
Citalopram 61% 67% 69.2% 70.4% 65.3%
Escitalopram 61% 66.7% 69.1% 67.1% 64.9%
Fluoxetine 69.9% 72.2% 75.2% 75% 73.5%
Paroxetine 60.5% 65.7% 71.5% 70.3% 60.5%
Sertraline 62.4% 67% 67.2% 69.8% 63.6%
Duloxetine 65.1% 69.3% 73.7% 75.1% 65.6%
Venlafaxine 61.1% 65.9% 69.5% 70.2% 60.6%
Amitriptyline 65.3% 71.8% 74.6% 75.7% 69%
Mirtazapine 57.5% 65.9% 65.5% 64.7% 58.5%
Agomelatine 65% 68.3% 69.7% 67.4% 62.1%
Age, median (IQR), years
Citalopram 51 (36–70) 54 (42–70) 63 (46–79) 55 (41–71) 56 (39–75)
Escitalopram 52 (37–69) 51 (39–63) 56 (42–73) 51 (38–67) 44 (32–59)
Fluoxetine 41 (29–54) 47 (36–57) 50 (39–63) 47 (37–59) 38 (26–51)
Paroxetine 44 (34–59) 49 (37–60) 53 (40–68) 49 (37–63) 45 (32–58)
Sertraline 44 (31–59) 52 (41–65) 62 (44–78) 61 (44–76) 43 (30–60)
Duloxetine 48 (37–60) 57 (47–70) 59 (46–73) 56 (45–68) 48 (37–61)
Venlafaxine 45 (33–57) 51 (40–61) 55 (43–70) 53 (42–67) 44 (32–58)
Amitriptyline 51 (41–65) 58 (47–71) 53 (40–67) 52 (39–65) 55 (43–68)
Mirtazapine 54 (40–72) 58 (47–73) 67 (49–81) 60 (45–76) 58 (41–76)
Agomelatine 46 (36–57) 52 (42–61) 54 (42–67) 51 (41–62) 45 (33–56)
IQR= interquartile range.
Table 2
Cumulative incidence of study antidepressant initiation at the end of study
period (per 1000 population).
Denmarka GePaRD,
Germanyb
EpiChron,
Aragon,
Spainc
SIDIAP,
Catalonia,
Spaina
Swedena
Citalopram 64.5 43.7 9.5 38.0 52.5
Escitalopram 14.5 7.3 47.5 21.1 18.3
Fluoxetine 4.7 6.3 15.5 17.0 10.0
Paroxetine 4.8 4.7 23.8 27.8 4.5
Sertraline 35.0 8.3 11.7 20.1 46.5
Duloxetine 9.5 7.5 21.6 9.7 11.2
Venlafaxine 22.2 13.9 10.9 11.1 16.9
Amitriptyline 10.0 29.2 20.6 24.2 26.4
Mirtazapine 42.5 35.0 21.8 14.5 45.0
Agomelatine 5.6 5.9 9.2 3.0 2.5
Total 213.3 161.8 192.0 186.5 233.8
Note: The estimated cumulative incidence of study antidepressant initiation at
the end of the study period was calculated by dividing the total number of
initiators during the study period (2009–2013/2014) of each antidepressant by
the total reference adult population in each data source at the end of 2013 or
2014 (depending on the end of the study period).
a Population reference: adult population in the data source at 01 January
2014.
b Population reference: average of the adult population average between the
size of the source population at the start of the study period (2009) and the end
of the study period (2013).
c Population reference: adult population in the data source at 01 January
2013.
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Except in Denmark where the cumulative incidence was lower (10 per
1000 population), amitriptyline had a similar cumulative incidence in
all populations (ranging from 21 to 29 per 1000 population). The cu-
mulative incidence for mirtazapine was the highest in Denmark, Ger-
many (where it was the second most commonly used antidepressant),
and Sweden (where it was the third). Finally, the use of agomelatine
was low in all populations, with a cumulative incidence below 10 per
1000 population in all data sources.
3.3. Baseline comorbidities of antidepressant initiators
The most prevalent comorbidities at baseline (percentage and 95%
confidence interval) in the study antidepressant initiators were hy-
pertension, diabetes, hyperlipidaemia, and obesity (Table 3). The
highest prevalence of hypertension was found among initiators of
mirtazapine in Aragon (55%) and Catalonia (38%) (Spain) and Sweden
(48%) and among initiators of amitriptyline in Denmark (38%). In
Germany, the highest prevalence of hypertension was found equal
among initiators of amitriptyline and mirtazapine (63%). A similar
pattern, although with lower prevalence compared with hypertension,
was observed for other comorbidities. Conversely, the percentage of
patients with obesity at baseline was higher among fluoxetine initiators
and lower for mirtazapine initiators.
3.4. Hospitalisations in the 12 months prior to start date among
antidepressant initiators
The number of hospitalisations among initiators of study anti-
depressants during the 12 months before the study start varied among
populations, although a common pattern emerged. Mirtazapine in-
itiators were more frequently hospitalised compared with initiators of
the remaining study antidepressants in Aragon and Catalonia, Spain,
and Sweden (percentages of at least one hospitalisation were 23%,
17%, and 33%, respectively) (Table 4). Although initiators of ami-
triptyline had the highest proportion of patients who had been hospi-
talised in the previous year in Denmark (37% of patients had at least 1
hospitalisation), the proportion of patients with recent hospitalisations
was also high for initiators of mirtazapine (33% of patients with at least
1 hospitalisation). Similarly, in Germany initiators of duloxetine and
escitalopram (56% and 48% of patients with at least one hospitalisa-
tion, respectively) had the highest proportion of patients who had been
hospitalised in the previous year, followed by initiators of mirtazapine
(47% of patients with at least one hospitalisation).
3.5. Patterns of antidepressant use among initiators
The recent use of any antidepressant during the 12 months prior to
the current treatment episode is presented in Fig. 1. In all populations,
citalopram initiators were among the patients with the highest pro-
portions of no antidepressant use in the 12 months prior to the current
treatment episode. Amitriptyline had the highest proportion with no
use in Aragon and Catalonia (Spain) and in Germany. Conversely, the
two SNRIs (duloxetine and venlafaxine) and agomelatine were the an-
tidepressants with the higher proportion of patients who used two or
more antidepressants during the 12 months prior to the current treat-
ment episode (Fig. 1). Among the five populations, the overall pro-
portion of initiators with no previous use of other study antidepressants
in the 12 months prior to the current treatment episode was highest in
Spain, Germany, and Denmark and lowest in Sweden.
Patterns regarding duration of the first treatment episode of current
use and percentage of all treatment episodes of current use with com-
bined use of other antidepressants during the study period are pre-
sented in Table 5. For all study antidepressants, the duration of the first
treatment episode of current use was slightly longer in Catalonia
(Spain) (range, 4 months for amitriptyline to 10 months for venla-
faxine) and shorter in Germany (range, 2 months for amitriptyline to 4
months for fluoxetine) than in the other populations. The median
duration of the first index episode was longer for venlafaxine initiators
and shorter for amitriptyline initiators in all populations except in
Sweden. The highest percentage of patients in the five populations who
were using combined antidepressants during their current treatment
episode was found in initiators of agomelatine, followed by venlafaxine
and duloxetine initiators (in Denmark, amitriptyline also had a high
percentage of multiple use).
4. Discussion
In this study, we characterised more than 4.8 million initiators of 10
antidepressants in Spain, Germany, Denmark, and Sweden. Overall,
citalopram was the most prescribed study antidepressant, followed by
mirtazapine. Agomelatine (one of the most recent study antidepressants
available on the market) and paroxetine, were the least commonly
Table 4
Number of hospitalisations among study antidepressant initiators of each of the study antidepressants during the 12 months before the cohort inclusion date, by data
source.
SSRIs SNRIs TCA NASSA Other
Citalopram Escitalopram Fluoxetine Paroxetine Sertraline Duloxetine Venlafaxine Amitriptyline Mirtazapine Agomelatine
Denmark
0 70.2% 68.4% 78.6% 76.9% 76.2% 73.6% 76.5% 62.9% 67.2% 77.8%
1 17.6% 17.7% 14.3% 14.4% 15.2% 15.9% 14.8% 20.3% 18.0% 14.2%
2+ 12.1% 13.8% 7.1% 8.7% 8.6% 10.5% 8.7% 16.8% 14.8% 8.0%
GePaRD
0 60.4% 52.0% 68.1% 65.2% 56.9% 44.1% 55.3% 56.7% 52.9% 53.9%
1+ 39.6% 48.0% 31.9% 34.8% 43.1% 55.9% 44.7% 43.3% 47.1% 46.1%
EpiChron, Aragon, Spain
0 84.2% 85.7% 89.5% 88.9% 82.7% 84.9% 86.1% 89.8% 76.7% 86.5%
1 10.8% 10.1% 7.7% 8.3% 11.5% 10.6% 10.1% 7.9% 15.0% 9.8%
2+ 5.0% 4.2% 2.8% 2.9% 5.8% 4.5% 3.9% 2.4% 8.3% 3.7%
SIDIAP, Catalonia, Spain
0 88.4% 88.8% 90.9% 91.4% 87.3% 88.7% 88.7% 90.1% 83.1% 91.4%
1 8.7% 8.2% 7.3% 6.8% 9.4% 8.7% 8.8% 7.8% 11.7% 6.5%
2+ 3.0% 3.0% 1.9% 1.8% 3.3% 2.7% 2.5% 2.1% 5.2% 2.1%
Sweden
0 73.8% 75.9% 80.2% 80.0% 79.3% 71.8% 76.7% 75.2% 66.8% 73.3%
1 13.8% 12.8% 11.8% 11.6% 12.2% 14.8% 13% 13.4% 15.8% 13.6%
2+ 12.4% 11.2% 8.0% 8.4% 8.5% 13.4% 10.3% 11.4% 17.5% 13.1%
NA=not applicable, NASSA=noradrenaline and specific serotonergic antidepressant, SNRI= serotonin-norepinephrine reuptake inhibitor, SSRI= selective ser-
otonin reuptake inhibitor, TCA= tricyclic antidepressant.
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prescribed antidepressants. Mirtazapine initiators were older compared
to initiators of other antidepressants. Consequently, mirtazapine in-
itiators had the highest percentage of comorbidities at baseline and also
more hospitalisations in the 12 months prior to start date. Fluoxetine
was the most common study antidepressant among younger and heal-
thier initiators. Finally, citalopram and amitriptyline were the anti-
depressants with the lowest percentages of initiators who had used
other antidepressant drugs in the 12 months prior to the current
treatment episode, while agomelatine and SNRIs (duloxetine and ven-
lafaxine) initiators had the highest percentage of antidepressants use in
the year prior to the current treatment episode.
The results of the present study, which highlight citalopram as the
most commonly prescribed among study antidepressant initiators in all
populations but in Aragon (Spain), where escitalopram was the most
often prescribed antidepressant, are in accordance with clinical guide-
lines to manage major depressive disorder in adults (Cipriani et al.,
2018; National Institute for Health and Clinical Excellence, 2018b). The
clinical guidelines for depression suggest using an SSRI (mostly citalo-
pram, fluoxetine, and sertraline) as first-line treatment in adults
(National Institute for Health and Clinical Excellence, 2018b). If clinical
response is not adequate, the guidelines suggest a different SSRI agent
or a newer generation antidepressant like mirtazapine, which was the
second most prescribed antidepressant in Denmark, Germany, and
Sweden. It was however unexpected that mirtazapine initiators in all
populations but Sweden had a low percentage of prior use of other
antidepressants in the 12 months prior to cohort inclusion, suggesting
that mirtazapine may to some extent be used as a first-line agent in the
studied populations. The faster onset of action and the more sedative
effect of mirtazapine compared with SSRIs in the acute phase of de-
pression might explain these results (Watanabe et al., 2011). Re-
imbursement policies vary by antidepressant in each of the partici-
pating countries, and this could potentially explain the observed
variability in patterns of use of antidepressants. As an example, the
study revealed differences in prescriptions in the two Spanish popula-
tions, with escitalopram being more frequently prescribed in Aragon,
while citalopram was the number one option in Catalonia.
Overall, more than 50% of the antidepressant initiators receiving
SSRIs (mostly citalopram and sertraline) had no prior use of other an-
tidepressants, and a very low proportion of these patients used two or
more antidepressants in the 12 months prior to current treatment
Fig. 1. Proportion of study antidepressants initiators by antidepressant treatment in the 12 months before drug initiation (no previous treatment, one antidepressant,
two or more antidepressants) NASSA=noradrenaline and specific serotonergic antidepressant, SNRI= serotonin-norepinephrine reuptake inhibitor,
SSRI= selective serotonin reuptake inhibitor, TCA= tricyclic antidepressant.
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Fig. 1. (continued)
Fig. 1. (continued)
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episode, except in Sweden. Also, most SSRI initiators in the five po-
pulations did not have combined use with other antidepressants during
the current treatment episode. Both results suggest that, in general,
citalopram and to a minor degree sertraline, escitalopram, paroxetine,
and fluoxetine were mostly used as first-line treatment and used in
monotherapy. On the other hand, the two SNRIs included in the study,
duloxetine and venlafaxine, as well as agomelatine were seemingly
mostly used as second-line treatment, in agreement with clinical
guidelines for major depression (National Institute for Health and
Clinical Excellence, 2018b). This interpretation is also supported by the
high proportion of patients who used two or more antidepressants in
the 12 months prior to start date as well as by the high percentage of
patients who used other antidepressants concomitantly during the
study period. However, of the antidepressants included in this study,
duloxetine, venlafaxine, and agomelatine are the ones introduced in the
European Union market more recently, which could explain these re-
sults.
The main results discussed in the present study are focused on
management of depression, but all the study antidepressants are also
used in other conditions, which may explain some of the results ob-
served in the present study. For example, the TCA amitriptyline was
mainly used as monotherapy, and use of other antidepressants in the 12
months prior to the current treatment episode was uncommon.
Amitriptyline is recommended as first-line treatment in the manage-
ment of neuropathic pain (Fornasari, 2017; National Institute for Health
and Clinical Excellence, 2018a) and can also be used in the context of
migraine, stress, and sleep disorders (Aarts et al., 2016; Moore et al.,
2012, 2015). For these indications, amitriptyline can be used as
monotherapy, which accords with the observations from Germany,
Sweden, and Spain, or in combination with pregabalin/gabapentin,
opioids, or SNRIs (Holbech et al., 2017). Finally, the two SNRIs in the
study, duloxetine and venlafaxine, as well as the SSRIs are approved
treatments for anxiety disorders (Aarts et al., 2016).
The present study revealed that initiators of study antidepressants
frequently had several comorbidities, hypertension being the most
frequent. Mirtazapine was the most prescribed antidepressant among
patients with a higher percentage of comorbidities at baseline, which is
probably related to the fact that mirtazapine initiators were the oldest
initiators in all populations (median age range, 54–67 years). The un-
ique adverse event profile of mirtazapine including sedation and in-
crease in appetite may justify its use in older patients compared with
other antidepressants (Watanabe et al., 2011). It is important to note
that mirtazapine and amitriptyline, particularly in the Nordic countries,
were the most commonly prescribed antidepressants among patients
presenting comorbidities such as hypertension, diabetes, or hyperlipi-
daemia, which does not reflect the clinical guidelines that recommend
the use of citalopram or sertraline in these patient groups
(National Institute for Health and Clinical Excellence, 2018b) which
may be partly explained for the approved use in other conditions.
Conversely, fluoxetine initiators were younger compared to mirtaza-
pine initiators and had the lowest percentage of comorbidities at
baseline among all study antidepressants. These results are likely as-
sociated with the high efficacy of fluoxetine in reducing depressive
symptoms in children and adolescents (Cipriani et al., 2016). For obe-
sity, the percentage was higher among fluoxetine initiators and lower
among mirtazapine initiators, which is in accordance with previous
evidence that relates mirtazapine to a greater risk of weight gain and
fluoxetine with weight loss (Gafoor et al., 2018). Because we were not
able to differentiate whether differences in prevalence of comorbidities
between countries reflected an actual variation or differences in the
type of data available in each population, this could not be further
interpreted.
5. Limitations
The results of the present study should be interpreted in the context
of its limitations. First, although the data sources provide detailed in-
formation on filled prescriptions, which can be considered complete,
this information may not reflect actual use. However, information on
dispensing more closely reflects actual use by the patients than in-
formation obtained by prescribing data (Pottegard et al., 2014). Second,
the present study used a new-user design and then focused on initiators
of each of the study antidepressants only. Therefore, prevalent users
have not been evaluated. Third, the lack of information on the indica-
tion of medications in the present study hampered the possibility of
studying the differences in the indications across the different study
antidepressants and data sources. For this reason, discussion on the
present study focuses on depression and not on other conditions that
can be treated with the study antidepressants. Fourth, only a selected
group of antidepressants have been included in the present study, based
on the list of antidepressants included in the Agomelatine PASS
(Pladevall, 2018), and therefore the results of this study did not include
all available antidepressants in the ATC N06A group. Finally, the het-
erogeneity of health care systems and of the type of data across data
sources needs to be considered when evaluating comorbidities asso-
ciated with the different antidepressants. Information recorded in SI-
DIAP (Catalonia, Spain) and EpiChron (Aragon, Spain) data sources is
based on primary care and hospital discharge electronic medical re-
cords, information recorded in the GePaRD (Germany) data source is
based on insurance claims from ambulatory care visits and hospitali-
sations, and information in Denmark and Sweden registers is based on
hospital diagnoses only.
On the other hand, the present study has a number of strengths. The
present study presented data from 2009 to 2014, the most recent period
reported in the literature. In addition, it is one of the largest drug uti-
lization studies on the use of antidepressants in Europe, including al-
most 5 million initiators in Spain, Germany, Denmark, and Sweden
covering a base population of more than 36 million people. Also, we
have studied a number of important comorbidities at baseline. Finally,
we have well-defined populations with prospectively collected data.
6. Conclusions
Results of this study conducted in Denmark, Germany, Spain, and
Sweden including 4.8 million initiators of study antidepressants suggest
that citalopram and mirtazapine are the most commonly used anti-
depressants, followed by other SSRIs (sertraline, escitalopram, parox-
etine, and fluoxetine). Mirtazapine was the second most used anti-
depressant in most of the populations. Agomelatine, which is commonly
used as second-line treatment, and paroxetine were the least used an-
tidepressants in the participating populations. Mirtazapine was the
antidepressant most commonly prescribed among older study anti-
depressant initiators and was the one with the highest percentage of
comorbidities in patients at baseline and with the highest number of
hospitalisations. Fluoxetine was commonly prescribed among young
patients with a low percentage of comorbidities at baseline.
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